AIMS: Dynamin-related protein1 (Drp1) is a large GTPase that mediates mitochondrial fission. We recently reported in Alzheimer's disease (AD) that S-nitrosylation of Drp1 (forming S-nitroso [SNO]-Drp1) results in GTPase hyperactivity and mitochondrial fragmentation, thus impairing bioenergetics and inducing synaptic damage and neuronal loss. Here, since aberrant mitochondrial dynamics are also key features of Huntington's disease (HD), we investigated whether formation of SNO-Drp1 contributes to the pathogenesis of HD in cell-based and animal models. RESULTS: We found that expression of mutant huntingtin (mutHTT) protein in primary cultured neurons triggers significant production of nitric oxide (NO). Consistent with this result, increased levels of SNO-Drp1 were found in the striatum of a transgenic mouse model of HD as well as in human postmortem brains from HD patients. Using specific fluorescence markers, we found that formation of SNO-Drp1 induced excessive mitochondrial fragmentation followed by loss of dendritic spines, signifying synaptic damage. These neurotoxic events were significantly abrogated after transfection with non-nitrosylatable mutant Drp1(C644A), or by the blocking of NO production using an nitric oxide synthase inhibitor. These findings suggest that SNO-Drp1 is a key mediator of mutHTT toxicity, and, thus, may represent a novel drug target for HD. INNOVATION AND CONCLUSION: Our findings indicate that aberrant S-nitrosylation of Drp1 is a prominent pathological feature of neurodegenerative diseases such as AD and HD. Moreover, the SNO-Drp1 signaling pathway links mutHTT neurotoxicity to a malfunction in mitochondrial dynamics, resulting in neuronal synaptic damage in HD.
AIMS: Dynamin-related protein1 (Drp1) is a large GTPase that mediates mitochondrial fission. We recently reported in Alzheimer's disease (AD) that S-nitrosylation of Drp1 (forming S-nitroso [SNO]-Drp1) results in GTPase hyperactivity and mitochondrial fragmentation, thus impairing bioenergetics and inducing synaptic damage and neuronal loss. Here, since aberrant mitochondrial dynamics are also key features of Huntington's disease (HD), we investigated whether formation of SNO-Drp1 contributes to the pathogenesis of HD in cell-based and animal models. RESULTS: We found that expression of mutant huntingtin (mutHTT) protein in primary cultured neurons triggers significant production of nitric oxide (NO). Consistent with this result, increased levels of SNO-Drp1 were found in the striatum of a transgenic mouse model of HD as well as in human postmortem brains from HDpatients. Using specific fluorescence markers, we found that formation of SNO-Drp1 induced excessive mitochondrial fragmentation followed by loss of dendritic spines, signifying synaptic damage. These neurotoxic events were significantly abrogated after transfection with non-nitrosylatable mutant Drp1(C644A), or by the blocking of NO production using an nitric oxide synthase inhibitor. These findings suggest that SNO-Drp1 is a key mediator of mutHTT toxicity, and, thus, may represent a novel drug target for HD. INNOVATION AND CONCLUSION: Our findings indicate that aberrant S-nitrosylation of Drp1 is a prominent pathological feature of neurodegenerative diseases such as AD and HD. Moreover, the SNO-Drp1 signaling pathway links mutHTT neurotoxicity to a malfunction in mitochondrial dynamics, resulting in neuronal synaptic damage in HD.
Authors: Michelle Gray; Dyna I Shirasaki; Carlos Cepeda; Véronique M André; Brian Wilburn; Xiao-Hong Lu; Jifang Tao; Irene Yamazaki; Shi-Hua Li; Yi E Sun; Xiao-Jiang Li; Michael S Levine; X William Yang Journal: J Neurosci Date: 2008-06-11 Impact factor: 6.167
Authors: Hongmei Li; Yingbei Chen; Adrienne F Jones; Richard H Sanger; Leon P Collis; Richard Flannery; Ewan C McNay; Tingxi Yu; Robert Schwarzenbacher; Blaise Bossy; Ella Bossy-Wetzel; Michael V L Bennett; Marc Pypaert; John A Hickman; Peter J S Smith; J Marie Hardwick; Elizabeth A Jonas Journal: Proc Natl Acad Sci U S A Date: 2008-02-04 Impact factor: 11.205
Authors: Shu-ichi Okamoto; Mahmoud A Pouladi; Maria Talantova; Dongdong Yao; Peng Xia; Dagmar E Ehrnhoefer; Rameez Zaidi; Arjay Clemente; Marcus Kaul; Rona K Graham; Dongxian Zhang; H-S Vincent Chen; Gary Tong; Michael R Hayden; Stuart A Lipton Journal: Nat Med Date: 2009-11-15 Impact factor: 53.440
Authors: Chang-Ki Oh; Abdullah Sultan; Joseph Platzer; Nima Dolatabadi; Frank Soldner; Daniel B McClatchy; Jolene K Diedrich; John R Yates; Rajesh Ambasudhan; Tomohiro Nakamura; Rudolf Jaenisch; Stuart A Lipton Journal: Cell Rep Date: 2017-11-21 Impact factor: 9.423
Authors: Haitham Amal; Boaz Barak; Vadiraja Bhat; Guanyu Gong; Brian A Joughin; Xin Wang; John S Wishnok; Guoping Feng; Steven R Tannenbaum Journal: Mol Psychiatry Date: 2018-07-09 Impact factor: 15.992
Authors: Audrey S Dickey; Dafne N Sanchez; Martin Arreola; Kunal R Sampat; Weiwei Fan; Nicolas Arbez; Sergey Akimov; Michael J Van Kanegan; Kohta Ohnishi; Stephen K Gilmore-Hall; April L Flores; Janice M Nguyen; Nicole Lomas; Cynthia L Hsu; Donald C Lo; Christopher A Ross; Eliezer Masliah; Ronald M Evans; Albert R La Spada Journal: Sci Transl Med Date: 2017-12-06 Impact factor: 17.956